Literature DB >> 21467042

Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites.

Jonathan H Foley1, Paul F Cook, Michael E Nesheim.   

Abstract

Partial digestion of fibrin by plasmin exposes C-terminal lysine residues, which comprise new binding sites for both plasminogen and tissue-type plasminogen activator (tPA). This binding increases the catalytic efficiency of plasminogen activation by 3000-fold compared with tPA alone. The activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrinolysis by removing these residues, which causes a 97% reduction in tPA catalytic efficiency. The aim of this study was to determine the kinetics of TAFIa-catalyzed lysine cleavage from fibrin degradation products and the kinetics of loss of plasminogen-binding sites. We show that the k(cat) and K(m) of Glu(1)-plasminogen (Glu-Pg)-binding site removal are 2.34 s(-1) and 142.6 nm, respectively, implying a catalytic efficiency of 16.21 μm(-1) s(-1). The corresponding values of Lys(77)/Lys(78)-plasminogen (Lys-Pg)-binding site removal are 0.89 s(-1) and 96 nm implying a catalytic efficiency of 9.23 μm(-1) s(-1). These catalytic efficiencies of plasminogen-binding site removal by TAFIa are the highest of any TAFIa-catalyzed reaction with a biological substrate reported to date and suggest that plasmin-modified fibrin is a primary physiological substrate for TAFIa. We also show that the catalytic efficiency of cleavage of all C-terminal lysine residues, whether they are involved in plasminogen binding or not, is 1.10 μm(-1) s(-1). Interestingly, this value increases to 3.85 μm(-1) s(-1) in the presence of Glu-Pg. These changes are due to a decrease in K(m). This suggests that an interaction between TAFIa and plasminogen comprises a component of the reaction mechanism, the plausibility of which was established by showing that TAFIa binds both Glu-Pg and Lys-Pg.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467042      PMCID: PMC3103306          DOI: 10.1074/jbc.M110.215061

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  The plasminogen (fibrinolytic) system.

Authors:  D Collen
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

Authors:  Mark Schneider; Michael Boffa; Ronald Stewart; Mona Rahman; Marlys Koschinsky; Michael Nesheim
Journal:  J Biol Chem       Date:  2001-10-29       Impact factor: 5.157

3.  Overall kinetic mechanism of saccharopine dehydrogenase from Saccharomyces cerevisiae.

Authors:  Hengyu Xu; Ann H West; Paul F Cook
Journal:  Biochemistry       Date:  2006-10-03       Impact factor: 3.162

4.  TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.

Authors:  L Bajzar; J Morser; M Nesheim
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

Review 5.  What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?

Authors:  J Morser; E C Gabazza; T Myles; L L K Leung
Journal:  J Thromb Haemost       Date:  2010-01-30       Impact factor: 5.824

6.  A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.

Authors:  Erin K T Neill; Ronald J Stewart; Mark M Schneider; Michael E Nesheim
Journal:  Anal Biochem       Date:  2004-07-15       Impact factor: 3.365

7.  Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro.

Authors:  J C Fredenburgh; M E Nesheim
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

8.  Activation and characterization of procarboxypeptidase B from human plasma.

Authors:  A K Tan; D L Eaton
Journal:  Biochemistry       Date:  1995-05-02       Impact factor: 3.162

9.  The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

Authors:  John B Walker; Laszlo Bajzar
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

10.  Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.

Authors:  L Bajzar; R Manuel; M E Nesheim
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  5 in total

1.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

2.  Limited proteolysis of fibrinogen by fibrinogenase from Echis multisquamatis venom.

Authors:  V O Chernyshenko
Journal:  Protein J       Date:  2015-04       Impact factor: 2.371

3.  Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

Authors:  Jonathan H Foley; Karl-Uwe Petersen; Catherine J Rea; Lori Harpell; Sandra Powell; David Lillicrap; Michael E Nesheim; Benny Sørensen
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

4.  Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.

Authors:  Virginie Bondu; Ron Schrader; Mary Ann Gawinowicz; Paul McGuire; Daniel A Lawrence; Brian Hjelle; Tione Buranda
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

Review 5.  Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms.

Authors:  Jordan R Yaron; Liqiang Zhang; Qiuyun Guo; Shelley E Haydel; Alexandra R Lucas
Journal:  Front Cardiovasc Med       Date:  2021-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.